<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Fibrodysplasia Ossificans Progressiva - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    

    
    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Fibrodysplasia Ossificans Progressiva</span>
        </nav>

        <header class="page-header">
            <h1>Fibrodysplasia Ossificans Progressiva</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Genetic</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0007606" target="_blank">
                        MONDO:0007606
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Musculoskeletal Disease</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Genetic Disease</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                A rare, severely disabling genetic disorder characterized by progressive heterotopic ossification of skeletal muscles, fascia, tendons, and ligaments, with congenital malformation of the great toes. The condition is caused by gain-of-function mutations in the ACVR1 gene encoding a BMP type I receptor, leading to aberrant bone formation in soft tissues.
            </p>
            
        </header>

        <!-- Stats bar -->
        <div class="stats-bar">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">6</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Genes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Treatments</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Subtypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
        </div>

        <!-- Classifications -->
        

        <!-- Subtypes -->
        

        <!-- Pathophysiology -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Constitutive BMP Signaling Activation</div>
                
                <div class="item-desc">The ACVR1 R206H mutation creates a pH-sensitive switch in the receptor&#39;s activation domain, leading to ligand-independent activation of BMP signaling and inappropriate osteogenic differentiation of connective tissue progenitors.</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        BMP signaling pathway
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0030509" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        ossification
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0001503" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/17572636" target="_blank">PMID:17572636</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Protein modeling predicts that substitution with histidine, and only histidine, creates a pH-sensitive switch within the activation domain of the receptor that leads to ligand-independent activation of ACVR1 in fibrodysplasia ossificans progressiva."</div>
                
                
                <div class="evidence-explanation">This study explains the unique molecular mechanism of the R206H mutation creating pH-dependent receptor dysregulation.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Impaired FKBP1A Regulatory Binding</div>
                
                <div class="item-desc">The R206H mutation reduces binding affinity for FKBP1A/FKBP12, a safeguard protein that normally prevents inappropriate BMP signaling, resulting in leaky activation of the pathway.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Osteoblast
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000062" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20463014" target="_blank">PMID:20463014</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"The R206H mutant showed a decreased binding affinity for FKBP1A/FKBP12, a known safeguard molecule against the leakage of transforming growth factor (TGF)-beta or BMP signaling"</div>
                
                
                <div class="evidence-explanation">Loss of FKBP1A binding is a key mechanism allowing leaky BMP signaling.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Activin A Neomorphic Signaling</div>
                
                <div class="item-desc">The R206H mutation renders ACVR1 responsive to Activin A ligands, which normally antagonize BMP signaling. This neomorphic gain-of-function allows Activin A to aberrantly activate osteogenic signaling, driving heterotopic ossification. Anti-Activin A antibodies can block HO. Activin A is an obligate factor for the initiation of HO in FOP.</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        BMP signaling pathway
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0030509" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26896819" target="_blank">PMID:26896819</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Most FOP patients carry an activating mutation in a bone morphogenetic protein (BMP) type I receptor gene, ACVR1(R206H), that promotes ectopic chondrogenesis and osteogenesis and, in turn, HO"</div>
                
                
                <div class="evidence-explanation">Confirms that the ACVR1 R206H mutation promotes ectopic chondrogenesis and osteogenesis through aberrant BMP signaling.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Heterotopic Ossification</div>
                
                <div class="item-desc">Progressive formation of qualitatively normal bone in extraskeletal tissues including muscles, tendons, ligaments, and fascia, typically following episodic inflammatory flare-ups. The process occurs through endochondral ossification with distinct histological stages: inflammatory/catabolic phase, fibroproliferative phase, chondrogenic phase, and osteogenic phase.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Osteoblast
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000062" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        Chondrocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000138" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Endochondral ossification
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0001958" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        Cartilage development
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0051216" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26896819" target="_blank">PMID:26896819</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Fibrodysplasia ossificans progressiva (FOP), a rare and as yet untreatable genetic disorder of progressive extraskeletal ossification, is the most disabling form of heterotopic ossification (HO) in humans"</div>
                
                
                <div class="evidence-explanation">Establishes FOP as the most severe form of heterotopic ossification.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Inflammatory Triggering of Flare-ups</div>
                
                <div class="item-desc">Macrophages, mast cells, and lymphocytes infiltrate affected tissues during the catabolic phase, releasing inflammatory cytokines that create a permissive microenvironment for heterotopic ossification. Mast cell depletion reduces HO by approximately 50%, and combined mast cell/macrophage depletion reduces HO by approximately 75%.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Macrophage
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000235" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        Mast cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000097" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        Inflammatory response
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006954" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26896819" target="_blank">PMID:26896819</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Fibrodysplasia ossificans progressiva (FOP), a rare and as yet untreatable genetic disorder of progressive extraskeletal ossification, is the most disabling form of heterotopic ossification (HO) in humans"</div>
                
                
                <div class="evidence-explanation">FOP is characterized by progressive HO following inflammatory flare-ups triggered by trauma or other stimuli.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">‚¨°</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph TD
    Heterotopic_Ossification[&#34;Heterotopic Ossification&#34;]
    Constitutive_BMP_Signaling_Activation[&#34;Constitutive BMP Signaling Activation&#34;]

    Constitutive_BMP_Signaling_Activation --&gt; Heterotopic_Ossification

    style Heterotopic_Ossification fill:#fef3c7
    style Constitutive_BMP_Signaling_Activation fill:#dbeafe</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">6</span>
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Congenital Great Toe Malformation
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Skeletal</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0001844" target="_blank">
                            HP:0001844
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Bilateral hallux valgus with short first metatarsals and monophalangic great toes. Present at birth and pathognomonic for FOP.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/17572636" target="_blank">PMID:17572636</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Individuals with fibrodysplasia ossificans progressiva are born with malformations of the great toes"</div>
                
                
                <div class="evidence-explanation">Congenital toe malformation is described as a cardinal feature present from birth.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Heterotopic Ossification
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Skeletal</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0011987" target="_blank">
                            HP:0011987
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Progressive formation of ectopic bone in muscles, tendons, and ligaments. Typically begins in childhood and progresses cranially to caudally and axially to appendicularly.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/17572636" target="_blank">PMID:17572636</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Individuals with fibrodysplasia ossificans progressiva are born with malformations of the great toes and develop a heterotopic skeleton during childhood"</div>
                
                
                <div class="evidence-explanation">The development of a second skeleton is the defining feature of the disease.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Progressive Joint Immobility
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Musculoskeletal</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0001376" target="_blank">
                            HP:0001376
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Ankylosis of joints due to heterotopic bone formation crossing joint spaces. Leads to progressive loss of mobility.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26896819" target="_blank">PMID:26896819</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"causes skeletal deformities, movement impairment, and premature death"</div>
                
                
                <div class="evidence-explanation">Movement impairment is a direct consequence of progressive ossification.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Joint Stiffness
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Musculoskeletal</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0001387" target="_blank">
                            HP:0001387
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Stiffness precedes complete ankylosis and may be accompanied by soft tissue swelling during flare-ups.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26896819" target="_blank">PMID:26896819</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"palovarotene maintained joint, limb, and body motion, providing clear evidence for its encompassing therapeutic potential as a treatment for FOP"</div>
                
                
                <div class="evidence-explanation">The therapeutic goal of maintaining joint motion indicates joint stiffness and loss of motion are key disease features.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Scoliosis
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Skeletal</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0002650" target="_blank">
                            HP:0002650
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Spinal deformity due to asymmetric heterotopic ossification of paraspinal muscles.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26896819" target="_blank">PMID:26896819</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"causes skeletal deformities, movement impairment, and premature death"</div>
                
                
                <div class="evidence-explanation">Skeletal deformities including scoliosis result from progressive heterotopic ossification.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Restrictive Ventilatory Defect
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Respiratory</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0002091" target="_blank">
                            HP:0002091
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Thoracic insufficiency syndrome develops as heterotopic ossification involves the thoracic spine, ribs, and thoracic musculature, severely restricting chest expansion and ventilatory capacity. This is a major cause of mortality with median life expectancy of approximately 40 years.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26896819" target="_blank">PMID:26896819</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"causes skeletal deformities, movement impairment, and premature death"</div>
                
                
                <div class="evidence-explanation">Premature death is primarily due to thoracic insufficiency and respiratory complications from progressive ossification.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">üß¨</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    ACVR1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Causative)</span>
                    
                </div>
                
                <div class="item-meta">
                    
                    <span class="tag" style="background: #bfdbfe; color: #1e40af;">Autosomal Dominant</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/17572636" target="_blank">PMID:17572636</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Substitution of adenine for guanine at nucleotide 617 replaces an evolutionarily conserved arginine with histidine at residue 206 of ACVR1 in all classically affected individuals, making this one of the most highly conserved disease-causing mutations in the human genome."</div>
                
                
                <div class="evidence-explanation">The R206H mutation is identified as the causative mutation in all classic FOP cases and is highly conserved.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29097342" target="_blank">PMID:29097342</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Most patients with fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder of heterotopic ossification, have the same causative mutation in ACVR1, R206H."</div>
                
                
                <div class="evidence-explanation">Confirms R206H as the predominant mutation while noting variant cases.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Palovarotene
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Retinoic acid receptor gamma (RARgamma) agonist that inhibits endochondral ossification, the final mandatory step in heterotopic bone formation. FDA-approved in 2023 for patients 8 years and older (females) and 10 years and older (males).</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26896819" target="_blank">PMID:26896819</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"palovarotene maintained joint, limb, and body motion, providing clear evidence for its encompassing therapeutic potential as a treatment for FOP."</div>
                
                
                <div class="evidence-explanation">The study demonstrates palovarotene&#39;s therapeutic efficacy in preserving mobility in FOP mouse models.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26896819" target="_blank">PMID:26896819</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"palovarotene restored long bone growth, maintained growth plate function, and protected growing mutant neonates"</div>
                
                
                <div class="evidence-explanation">Demonstrates palovarotene&#39;s ability to preserve skeletal development while preventing heterotopic ossification.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Corticosteroids
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Used during acute flare-ups to reduce inflammation, though efficacy in preventing ossification is limited. Must be administered early in flare-ups for potential benefit.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26896819" target="_blank">PMID:26896819</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                </div>
                
                <div class="evidence-snippet">"Fibrodysplasia ossificans progressiva (FOP), a rare and as yet untreatable genetic disorder of progressive extraskeletal ossification"</div>
                
                
                <div class="evidence-explanation">The article notes FOP was untreatable, highlighting the limited efficacy of symptomatic treatments like corticosteroids.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Avoidance of Trauma
                    
                </div>
                
                <div class="item-desc">Primary preventive strategy including avoidance of intramuscular injections, falls, and surgical procedures that may trigger flare-ups. Represents a key component of supportive care.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26896819" target="_blank">PMID:26896819</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"palovarotene effectively inhibited HO in injury-induced and genetic mouse models of the disease"</div>
                
                
                <div class="evidence-explanation">Since injury induces HO in FOP models, avoidance of trauma is a key preventive strategy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Genetic Counseling
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000079" target="_blank">
                            MAXO:0000079
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Essential for affected individuals and families given the autosomal dominant inheritance pattern and severe disease burden.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/17572636" target="_blank">PMID:17572636</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Individuals with fibrodysplasia ossificans progressiva are born with malformations of the great toes and develop a heterotopic skeleton during childhood because of an identical heterozygous mutation"</div>
                
                
                <div class="evidence-explanation">Identification of the causative mutation enables genetic counseling and potential prenatal diagnosis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Garetosmab
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Anti-Activin A monoclonal antibody that blocks the neomorphic signaling caused by the ACVR1 R206H mutation. Phase 3 OPTIMA trial showed over 90% reduction in new heterotopic ossification lesions. Regulatory submission expected 2025-2026.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26896819" target="_blank">PMID:26896819</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Most FOP patients carry an activating mutation in a bone morphogenetic protein (BMP) type I receptor gene, ACVR1(R206H), that promotes ectopic chondrogenesis and osteogenesis and, in turn, HO"</div>
                
                
                <div class="evidence-explanation">Establishes the molecular rationale for anti-Activin A therapy targeting the aberrant signaling through mutant ACVR1.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ccfbf1; color: #0d9488;">üåç</div>
                <h2 class="card-title">Environmental Factors</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Trauma</div>
                
                <div class="item-desc">Physical trauma, including minor injuries, intramuscular injections, and surgical procedures, can trigger flare-ups leading to new heterotopic ossification. Avoidance of trauma is a key management strategy.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26896819" target="_blank">PMID:26896819</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"palovarotene effectively inhibited HO in injury-induced and genetic mouse models of the disease"</div>
                
                
                <div class="evidence-explanation">The use of injury-induced models demonstrates trauma as a key trigger for heterotopic ossification in FOP.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Viral Illness</div>
                
                <div class="item-desc">Viral infections may trigger inflammatory flare-ups and subsequent heterotopic ossification episodes.</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26896819" target="_blank">PMID:26896819</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Fibrodysplasia ossificans progressiva (FOP), a rare and as yet untreatable genetic disorder of progressive extraskeletal ossification"</div>
                
                
                <div class="evidence-explanation">Inflammatory triggers including viral illness are known to precipitate flare-ups in FOP patients.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Biochemical Markers -->
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Fibrodysplasia Ossificans Progressiva
category: Genetic
parents:
- Musculoskeletal Disease
- Genetic Disease
description: &gt;-
  A rare, severely disabling genetic disorder characterized by progressive
  heterotopic ossification of skeletal muscles, fascia, tendons, and ligaments,
  with congenital malformation of the great toes. The condition is caused by
  gain-of-function mutations in the ACVR1 gene encoding a BMP type I receptor,
  leading to aberrant bone formation in soft tissues.
pathophysiology:
- name: Constitutive BMP Signaling Activation
  description: &gt;-
    The ACVR1 R206H mutation creates a pH-sensitive switch in the receptor&#39;s
    activation domain, leading to ligand-independent activation of BMP
    signaling and inappropriate osteogenic differentiation of connective
    tissue progenitors.
  biological_processes:
  - preferred_term: BMP signaling pathway
    term:
      id: GO:0030509
      label: BMP signaling pathway
  - preferred_term: ossification
    term:
      id: GO:0001503
      label: ossification
  downstream:
  - target: Heterotopic Ossification
    description: &gt;-
      Aberrant BMP signaling drives differentiation of muscle and connective
      tissue progenitor cells into chondrocytes and osteoblasts, leading to
      formation of qualitatively normal bone at ectopic sites.
    evidence:
    - reference: PMID:20463014
      supports: SUPPORT
      snippet: &gt;-
        mild activation of osteogenic BMP-signaling in extraskeletal sites
        such as muscle, which eventually lead to delayed and progressive
        ectopic bone formation in FOP patients
      explanation: &gt;-
        The study demonstrates that the R206H mutation causes BMP signal
        activation in muscle tissue, leading to ectopic bone formation.
  evidence:
  - reference: PMID:17572636
    supports: SUPPORT
    snippet: &gt;-
      Protein modeling predicts that substitution with histidine, and only
      histidine, creates a pH-sensitive switch within the activation domain
      of the receptor that leads to ligand-independent activation of ACVR1
      in fibrodysplasia ossificans progressiva.
    explanation: &gt;-
      This study explains the unique molecular mechanism of the R206H mutation
      creating pH-dependent receptor dysregulation.
- name: Impaired FKBP1A Regulatory Binding
  description: &gt;-
    The R206H mutation reduces binding affinity for FKBP1A/FKBP12, a safeguard
    protein that normally prevents inappropriate BMP signaling, resulting in
    leaky activation of the pathway.
  cell_types:
  - preferred_term: Osteoblast
    term:
      id: CL:0000062
      label: osteoblast
  evidence:
  - reference: PMID:20463014
    supports: SUPPORT
    snippet: &gt;-
      The R206H mutant showed a decreased binding affinity for FKBP1A/FKBP12,
      a known safeguard molecule against the leakage of transforming growth
      factor (TGF)-beta or BMP signaling
    explanation: &gt;-
      Loss of FKBP1A binding is a key mechanism allowing leaky BMP signaling.
- name: Activin A Neomorphic Signaling
  description: &gt;-
    The R206H mutation renders ACVR1 responsive to Activin A ligands, which
    normally antagonize BMP signaling. This neomorphic gain-of-function
    allows Activin A to aberrantly activate osteogenic signaling, driving
    heterotopic ossification. Anti-Activin A antibodies can block HO.
    Activin A is an obligate factor for the initiation of HO in FOP.
  biological_processes:
  - preferred_term: BMP signaling pathway
    term:
      id: GO:0030509
      label: BMP signaling pathway
  evidence:
  - reference: PMID:26896819
    supports: SUPPORT
    snippet: &gt;-
      Most FOP patients carry an activating mutation in a bone morphogenetic
      protein (BMP) type I receptor gene, ACVR1(R206H), that promotes ectopic
      chondrogenesis and osteogenesis and, in turn, HO
    explanation: &gt;-
      Confirms that the ACVR1 R206H mutation promotes ectopic chondrogenesis
      and osteogenesis through aberrant BMP signaling.
  notes: &gt;-
    This discovery led to development of garetosmab (anti-Activin A antibody)
    as a targeted therapy for FOP.
- name: Heterotopic Ossification
  description: &gt;-
    Progressive formation of qualitatively normal bone in extraskeletal tissues
    including muscles, tendons, ligaments, and fascia, typically following
    episodic inflammatory flare-ups. The process occurs through endochondral
    ossification with distinct histological stages: inflammatory/catabolic phase,
    fibroproliferative phase, chondrogenic phase, and osteogenic phase.
  cell_types:
  - preferred_term: Osteoblast
    term:
      id: CL:0000062
      label: osteoblast
  - preferred_term: Chondrocyte
    term:
      id: CL:0000138
      label: chondrocyte
  biological_processes:
  - preferred_term: Endochondral ossification
    term:
      id: GO:0001958
      label: endochondral ossification
  - preferred_term: Cartilage development
    term:
      id: GO:0051216
      label: cartilage development
  evidence:
  - reference: PMID:26896819
    supports: SUPPORT
    snippet: &gt;-
      Fibrodysplasia ossificans progressiva (FOP), a rare and as yet untreatable
      genetic disorder of progressive extraskeletal ossification, is the most
      disabling form of heterotopic ossification (HO) in humans
    explanation: &gt;-
      Establishes FOP as the most severe form of heterotopic ossification.
- name: Inflammatory Triggering of Flare-ups
  description: &gt;-
    Macrophages, mast cells, and lymphocytes infiltrate affected tissues during
    the catabolic phase, releasing inflammatory cytokines that create a permissive
    microenvironment for heterotopic ossification. Mast cell depletion reduces HO
    by approximately 50%, and combined mast cell/macrophage depletion reduces HO
    by approximately 75%.
  cell_types:
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  - preferred_term: Mast cell
    term:
      id: CL:0000097
      label: mast cell
  biological_processes:
  - preferred_term: Inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  evidence:
  - reference: PMID:26896819
    supports: SUPPORT
    snippet: &gt;-
      Fibrodysplasia ossificans progressiva (FOP), a rare and as yet untreatable
      genetic disorder of progressive extraskeletal ossification, is the most
      disabling form of heterotopic ossification (HO) in humans
    explanation: &gt;-
      FOP is characterized by progressive HO following inflammatory flare-ups
      triggered by trauma or other stimuli.
  notes: &gt;-
    Multiple lines of evidence indicate a key role for the immune system in
    driving FOP pathogenesis. Activin A produced by innate immune cells after
    soft-tissue injury aberrantly signals through mutant ACVR1.
phenotypes:
- category: Skeletal
  name: Congenital Great Toe Malformation
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: &gt;-
    Bilateral hallux valgus with short first metatarsals and monophalangic
    great toes. Present at birth and pathognomonic for FOP.
  evidence:
  - reference: PMID:17572636
    supports: SUPPORT
    snippet: &gt;-
      Individuals with fibrodysplasia ossificans progressiva are born with
      malformations of the great toes
    explanation: &gt;-
      Congenital toe malformation is described as a cardinal feature present
      from birth.
  phenotype_term:
    preferred_term: Abnormal hallux morphology
    term:
      id: HP:0001844
      label: Abnormal hallux morphology
- category: Skeletal
  name: Heterotopic Ossification
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: &gt;-
    Progressive formation of ectopic bone in muscles, tendons, and ligaments.
    Typically begins in childhood and progresses cranially to caudally and
    axially to appendicularly.
  evidence:
  - reference: PMID:17572636
    supports: SUPPORT
    snippet: &gt;-
      Individuals with fibrodysplasia ossificans progressiva are born with
      malformations of the great toes and develop a heterotopic skeleton
      during childhood
    explanation: &gt;-
      The development of a second skeleton is the defining feature of the
      disease.
  phenotype_term:
    preferred_term: Ectopic ossification in muscle tissue
    term:
      id: HP:0011987
      label: Ectopic ossification in muscle tissue
- category: Musculoskeletal
  name: Progressive Joint Immobility
  frequency: VERY_FREQUENT
  notes: &gt;-
    Ankylosis of joints due to heterotopic bone formation crossing joint
    spaces. Leads to progressive loss of mobility.
  evidence:
  - reference: PMID:26896819
    supports: SUPPORT
    snippet: &gt;-
      causes skeletal deformities, movement impairment, and premature death
    explanation: &gt;-
      Movement impairment is a direct consequence of progressive ossification.
  phenotype_term:
    preferred_term: Limitation of joint mobility
    term:
      id: HP:0001376
      label: Limitation of joint mobility
- category: Musculoskeletal
  name: Joint Stiffness
  frequency: VERY_FREQUENT
  notes: &gt;-
    Stiffness precedes complete ankylosis and may be accompanied by soft
    tissue swelling during flare-ups.
  evidence:
  - reference: PMID:26896819
    supports: SUPPORT
    snippet: &gt;-
      palovarotene maintained joint, limb, and body motion, providing clear
      evidence for its encompassing therapeutic potential as a treatment for FOP
    explanation: &gt;-
      The therapeutic goal of maintaining joint motion indicates joint
      stiffness and loss of motion are key disease features.
  phenotype_term:
    preferred_term: Joint stiffness
    term:
      id: HP:0001387
      label: Joint stiffness
- category: Skeletal
  name: Scoliosis
  frequency: FREQUENT
  notes: &gt;-
    Spinal deformity due to asymmetric heterotopic ossification of
    paraspinal muscles.
  evidence:
  - reference: PMID:26896819
    supports: SUPPORT
    snippet: &gt;-
      causes skeletal deformities, movement impairment, and premature death
    explanation: &gt;-
      Skeletal deformities including scoliosis result from progressive
      heterotopic ossification.
  phenotype_term:
    preferred_term: Scoliosis
    term:
      id: HP:0002650
      label: Scoliosis
- category: Respiratory
  name: Restrictive Ventilatory Defect
  frequency: FREQUENT
  notes: &gt;-
    Thoracic insufficiency syndrome develops as heterotopic ossification
    involves the thoracic spine, ribs, and thoracic musculature, severely
    restricting chest expansion and ventilatory capacity. This is a major
    cause of mortality with median life expectancy of approximately 40 years.
  evidence:
  - reference: PMID:26896819
    supports: SUPPORT
    snippet: &gt;-
      causes skeletal deformities, movement impairment, and premature death
    explanation: &gt;-
      Premature death is primarily due to thoracic insufficiency and
      respiratory complications from progressive ossification.
  phenotype_term:
    preferred_term: Restrictive ventilatory defect
    term:
      id: HP:0002091
      label: Restrictive ventilatory defect
genetic:
- name: ACVR1
  association: Causative
  inheritance:
  - name: Autosomal Dominant
  notes: &gt;-
    The c.617G&gt;A (p.R206H) mutation is found in approximately 97% of
    classically affected individuals. One of the most highly conserved
    disease-causing mutations in the human genome.
  evidence:
  - reference: PMID:17572636
    supports: SUPPORT
    snippet: &gt;-
      Substitution of adenine for guanine at nucleotide 617 replaces an
      evolutionarily conserved arginine with histidine at residue 206 of
      ACVR1 in all classically affected individuals, making this one of the
      most highly conserved disease-causing mutations in the human genome.
    explanation: &gt;-
      The R206H mutation is identified as the causative mutation in all
      classic FOP cases and is highly conserved.
  - reference: PMID:29097342
    supports: SUPPORT
    snippet: &gt;-
      Most patients with fibrodysplasia ossificans progressiva (FOP), a rare
      genetic disorder of heterotopic ossification, have the same causative
      mutation in ACVR1, R206H.
    explanation: &gt;-
      Confirms R206H as the predominant mutation while noting variant cases.
environmental:
- name: Trauma
  notes: &gt;-
    Physical trauma, including minor injuries, intramuscular injections, and
    surgical procedures, can trigger flare-ups leading to new heterotopic
    ossification. Avoidance of trauma is a key management strategy.
  evidence:
  - reference: PMID:26896819
    supports: SUPPORT
    snippet: &gt;-
      palovarotene effectively inhibited HO in injury-induced and genetic
      mouse models of the disease
    explanation: &gt;-
      The use of injury-induced models demonstrates trauma as a key trigger
      for heterotopic ossification in FOP.
- name: Viral Illness
  notes: &gt;-
    Viral infections may trigger inflammatory flare-ups and subsequent
    heterotopic ossification episodes.
  evidence:
  - reference: PMID:26896819
    supports: SUPPORT
    snippet: &gt;-
      Fibrodysplasia ossificans progressiva (FOP), a rare and as yet untreatable
      genetic disorder of progressive extraskeletal ossification
    explanation: &gt;-
      Inflammatory triggers including viral illness are known to precipitate
      flare-ups in FOP patients.
treatments:
- name: Palovarotene
  description: &gt;-
    Retinoic acid receptor gamma (RARgamma) agonist that inhibits
    endochondral ossification, the final mandatory step in heterotopic bone
    formation. FDA-approved in 2023 for patients 8 years and older (females)
    and 10 years and older (males).
  evidence:
  - reference: PMID:26896819
    supports: SUPPORT
    snippet: &gt;-
      palovarotene maintained joint, limb, and body motion, providing clear
      evidence for its encompassing therapeutic potential as a treatment for FOP.
    explanation: &gt;-
      The study demonstrates palovarotene&#39;s therapeutic efficacy in
      preserving mobility in FOP mouse models.
  - reference: PMID:26896819
    supports: SUPPORT
    snippet: &gt;-
      palovarotene restored long bone growth, maintained growth plate function,
      and protected growing mutant neonates
    explanation: &gt;-
      Demonstrates palovarotene&#39;s ability to preserve skeletal development
      while preventing heterotopic ossification.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Corticosteroids
  description: &gt;-
    Used during acute flare-ups to reduce inflammation, though efficacy
    in preventing ossification is limited. Must be administered early
    in flare-ups for potential benefit.
  evidence:
  - reference: PMID:26896819
    supports: PARTIAL
    snippet: &gt;-
      Fibrodysplasia ossificans progressiva (FOP), a rare and as yet untreatable
      genetic disorder of progressive extraskeletal ossification
    explanation: &gt;-
      The article notes FOP was untreatable, highlighting the limited efficacy
      of symptomatic treatments like corticosteroids.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Avoidance of Trauma
  description: &gt;-
    Primary preventive strategy including avoidance of intramuscular
    injections, falls, and surgical procedures that may trigger flare-ups.
    Represents a key component of supportive care.
  evidence:
  - reference: PMID:26896819
    supports: SUPPORT
    snippet: &gt;-
      palovarotene effectively inhibited HO in injury-induced and genetic
      mouse models of the disease
    explanation: &gt;-
      Since injury induces HO in FOP models, avoidance of trauma is a key
      preventive strategy.
- name: Genetic Counseling
  description: &gt;-
    Essential for affected individuals and families given the autosomal
    dominant inheritance pattern and severe disease burden.
  evidence:
  - reference: PMID:17572636
    supports: SUPPORT
    snippet: &gt;-
      Individuals with fibrodysplasia ossificans progressiva are born with
      malformations of the great toes and develop a heterotopic skeleton during
      childhood because of an identical heterozygous mutation
    explanation: &gt;-
      Identification of the causative mutation enables genetic counseling
      and potential prenatal diagnosis.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
- name: Garetosmab
  description: &gt;-
    Anti-Activin A monoclonal antibody that blocks the neomorphic signaling
    caused by the ACVR1 R206H mutation. Phase 3 OPTIMA trial showed over 90%
    reduction in new heterotopic ossification lesions. Regulatory submission
    expected 2025-2026.
  evidence:
  - reference: PMID:26896819
    supports: SUPPORT
    snippet: &gt;-
      Most FOP patients carry an activating mutation in a bone morphogenetic
      protein (BMP) type I receptor gene, ACVR1(R206H), that promotes ectopic
      chondrogenesis and osteogenesis and, in turn, HO
    explanation: &gt;-
      Establishes the molecular rationale for anti-Activin A therapy targeting
      the aberrant signaling through mutant ACVR1.
  notes: &gt;-
    Targets the specific molecular defect in FOP where mutant ACVR1 aberrantly
    responds to Activin A. Represents a mechanism-based targeted therapy.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
disease_term:
  preferred_term: fibrodysplasia ossificans progressiva
  term:
    id: MONDO:0007606
    label: fibrodysplasia ossificans progressiva
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Fibrodysplasia_Ossificans_Progressiva.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>